Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 40,985 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 40,985 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $3,769,800.30. Following the completion of the sale, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $17,872,541.82. The trade was a 17.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Christopher Peetz also recently made the following trade(s):

• On Monday, February 2nd, Christopher Peetz sold 9,108 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $103.30, for a total transaction of $940,856.40.
• On Monday, January 26th, Christopher Peetz sold 6,831 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $96.19, for a total transaction of $657,073.89.
• On Thursday, January 22nd, Christopher Peetz sold 7,098 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total transaction of $662,456.34.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $96.55 on Wednesday. The company has a fifty day moving average price of $96.13 and a two-hundred day moving average price of $81.00. Mirum Pharmaceuticals, Inc. has a one year low of $36.88 and a one year high of $109.28. The stock has a market cap of $5.83 billion, a P/E ratio of -201.14 and a beta of 0.52. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.13). The firm had revenue of $148.93 million for the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The firm’s revenue for the quarter was up 49.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.00 earnings per share. As a group, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum completed enrollment in the Phase 3 EXPAND study of LIVMARLI (maralixibat) for additional rare cholestatic liver diseases, a key clinical milestone that keeps the program on track; topline data are expected in Q4 2026. This is a material near‑term catalyst that can materially re‑rate the stock if results are positive. Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli Mirum Completes Enrollment (Yahoo)
• Negative Sentiment: Multiple insiders (CEO Christopher Peetz, COO Peter Radovich, CFO Eric Bjerkholt, SVP Jolanda Howe and Joanne Quan) sold meaningful blocks of shares on March 16 — collectively several million dollars at an average price of ~$91.98 — reducing their holdings by double‑digit percentages. Large, clustered insider sales can be perceived as profit‑taking or concern about near‑term upside and may put pressure on the stock even though insiders still retain significant equity. SEC filings: Peetz Form 4 Radovich Form 4 Bjerkholt Form 4 Howe Form 4 Quan Form 4

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently bought and sold shares of MIRM. Janus Henderson Group PLC grew its position in shares of Mirum Pharmaceuticals by 21.4% in the fourth quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock valued at $479,050,000 after purchasing an additional 1,067,722 shares during the last quarter. Eventide Asset Management LLC lifted its holdings in Mirum Pharmaceuticals by 4.4% during the 2nd quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock worth $134,224,000 after purchasing an additional 110,485 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Mirum Pharmaceuticals by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock worth $205,065,000 after purchasing an additional 50,720 shares during the last quarter. State Street Corp boosted its stake in Mirum Pharmaceuticals by 59.2% in the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after purchasing an additional 797,088 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in Mirum Pharmaceuticals by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock valued at $112,196,000 after purchasing an additional 137,087 shares during the period.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Evercore set a $126.00 price objective on Mirum Pharmaceuticals in a research note on Wednesday, March 4th. Royal Bank Of Canada reduced their target price on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Leerink Partners decreased their target price on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. TD Cowen increased their price target on Mirum Pharmaceuticals from $115.00 to $117.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, HC Wainwright raised their price target on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a report on Monday, January 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $117.00.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.